✦ LIBER ✦

329 Antitumor activity in preclinical xenograft models of OSI-930, a novel selective tyrosine kinase inhibitor

✍ Scribed by S.L. Winski; M.A. Bittner; P. Briner; E.N. Brown; A.R. Cooke; A. Crew; C. Hidden; C. Pirrit; M.S. Srebernak; D.L. Emerson

Book ID: 118621511
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 154 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80336-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

413 Pharmacokinetic/pharmacodynamic anal

413 Pharmacokinetic/pharmacodynamic analysis of OSI-930, a novel selective tyrosine kinase inhibitor with anti-tumor activity

✍ A. Garton; J. Kahler; L. Castaldo; Y. Yao; A. Franks; D. Henninger; M. Srebernak 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 289 KB

394 Inhibition of Kit-dependent tumor gr

394 Inhibition of Kit-dependent tumor growth by OSI-930, a novel selective tyrosine kinase inhibitor

✍ A.J. Garton; L. Castaldo; J. Kahler; M. O'Connor; S. Nitzan; S. Winski; M. Srebe 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Antitumor activity of HER1/EGFR tyrosine

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

✍ Jianping Chen; Melissa Smith; Kenneth Kolinsky; Violeta Adames; Nila Mehta; Luke 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 480 KB

Antitumour activity of oral E7080, a nov

Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts

✍ Skjalg Bruheim; Alexandr Kristian; Toshimitsu Uenaka; Zhenhe Suo; Akihiko Tsuruo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 588 KB

## Abstract E7080 is an inhibitor of multiple tyrosine kinases, several of which have pro‐angiogenic properties, including receptors for VEGF, FGF, SCF and PDGF. We undertook our study to evaluate the preclinical activity of E7080 in human sarcomas. The antitumour activity of orally administered E7

250 ORAL OXA-01, a novel potent mTORC1/T

250 ORAL OXA-01, a novel potent mTORC1/TORC2 kinase inhibitor, demonstrates broad spectrum antitumor activity in preclinical models of human cancer

✍ P.C. Gokhale; S.V. Bhagwat; A.P. Crew; A. Cooke; C. Mantis; J.E. Workman; D. Lan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Identification of AKN-032, a novel 2-ami

Identification of AKN-032, a novel 2-aminopyrazine tyrosine kinase inhibitor, with significant preclinical activity in acute myeloid leukemia

✍ Anna Eriksson; Martin Höglund; Elin Lindhagen; Anna Åleskog; Sadia Bashir Hassan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 517 KB